Expression of Shelterin Component POT1 Is Associated with Decreased Telomere Length and Immunity Condition in Humans with Severe Aplastic Anemia

Table 4

Telomere length of SAA patients and controls.

Number	Ages (y)	Group	TRF (kb)
1	69	1	7.61
2	60	1	4.76
3	16	1	4.33
4	26	1	3.52
5	44	1	3.54
6	33	1	3.92
7	49	1	4.74
8	5	1	3.29
9	20	1	6.30
10	5	2	8.07
11	18	2	4.66
12	19	2	7.40
13	20	2	7.21
14	20	2	7.00
15	23	2	6.05
16	25	2	5.98
17	27	2	5.98
18	29	2	8.78
19	31	2	4.31
20	36	2	8.83
21	45	2	8.38
22	47	2	8.56
23	48	2	5.96
24	18	3	13.45
25	67	3	7.40
26	7	3	16.57
27	35	3	10.41
28	37	3	19.82
29	25	3	9.20
30	47	3	6.12
31	48	3	7.08
32	52	3	6.12
33	15	3	20.34

Group 1: untreated SAA patients (𝑛=9).
Group 2: recovering SAA patients (𝑛=14).
Group 3: controls (𝑛=10).